Pathophysiology and treatment of iron overload in thalassemia patients in tropical countries

Advances in Experimental Medicine and Biology

Volumn 531, Issue , 2003, Pages 57-68

  Marx, J J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 4 PYRIDONE DERIVATIVE; BLEOMYCIN; CP 502; CYTOSTATIC AGENT; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DOXORUBICIN; HYDROXYL RADICAL; IRON; IRON CHELATING AGENT; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRALGIA; ASIA; CONFERENCE PAPER; CONTROLLED STUDY; CYTOSTASIS; ERYTHROBLAST; FEMALE; GASTROINTESTINAL SYMPTOM; HEMOCHROMATOSIS; HEMOGLOBIN SYNTHESIS; HUMAN; HUMAN CELL; IRON ABSORPTION; IRON BALANCE; IRON CHELATION; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; IRON RESPONSIVE ELEMENT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MUCOSA CELL; MYALGIA; NONHUMAN; PATHOPHYSIOLOGY; PHLEBOTOMY; PRIORITY JOURNAL; RAT; THALASSEMIA; TREATMENT INDICATION; TROPICS; ZINC DEFICIENCY;

ANIMALIA;

EID: 0041883805     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0059-9_5     Document Type: Conference Paper

References (24)

1. Andrews, N.C., 2002, A genetic view of iron homeostasis. Semin. Hematol., 39: 227-234.
2. Breuer, W., Hershko, C., and Cabantchik, Z.I., 2000, The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci., 23: 185-192.
3. Brissot, P., Guyader, D., Loreal, O., Laine, F., Guillygomarc'h, A., Moirand, R., and Deugnier, Y., 2000, Clinical aspects of haemochromatosis. Transfus. Sci., 23: 193-200.
4. Brizzi, P., Isaja, T., D'Agata, A., Malaguarnera, L., Malaguarnera, M., and Musumeci, S., 2002, Oxidized LDL antibodies (OLAB) in patients with beta-thalassemia major. J. Atheroscler. Thromb., 9: 139-144.
5. de Valk, B., Addicks, M.A., Gosriwatana, I., Lu, S., Hider, R.C., and Marx, J.J.M., 2000, Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur. J. Clin. Invest., 30: 248-251.
6. Hider, R.C., 2002, Nature of nontransferrin-bound iron. Eur. J. Clin. Invest., 32 Suppl 1: 50-54.
7. Hider, R.C., Liu, Z.D., and Piyamongkol, S., 2000, The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe(3+) values. Transfus. Sci., 23: 201-209.
8. Kaltwasser, J.P., Werner, E., Schalk, K., Hansen, C., Gottschalk, R., and Seidl, C., 1998, Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut, 43: 699-704.
9. Kontoghiorghes, G.J., Agarwal, M.B., Grady, R.W., Kolnagou, A., and Marx, J.J.M., 2000a, Deferiprone for thalassaemia. Lancet, 356: 428-429.
10. Kontoghiorghes, G.J., Pattichi, K., Hadjigavriel, M., and Kolnagou, A., 2000b, Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus. Sci., 23: 211-223.
11. Kuhn, L.C., 1991, mRNA-protein interactions regulate critical pathways in cellular iron metabolism. Br. J. Haematol., 79: 1-5.
12. Loreal, O., Gosriwatana, I., Guyader, D., Porter, J., Brissot, P., and Hider, R.C., 2000, Determination of non-transferrin-bound iron in genetic haemochromatosis using a new HPLC-based method. J. Hepatol., 32: 727-733.
13. Marx, J.J.M., 2002, Iron and infection: competition between host and microbes for a precious element. Best. Pract. Res. Clin. Haematol., 15: 411-426.
14. Marx, J.J.M., and van Asbeck, B.S., 1996, Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta Haematol., 95: 49-62.
15. Marx, J.J.M., and Santos, M., 2001, Pathophysiology of iron deficiency and iron overload in man. In Inorganic biochemistry of iron metabolism (R. Crichton, J.R. Boelaert, V. Braun, K. Hantke, J. M. M. Marx, M. Santos, and R. Ward, eds.), John Wiley and Sons, Chichester, pp. 207-233.
16. Moura, E., Noordermeer, M.A., Verhoeven, N., Verheul, A.F., and Marx, J.J.M., 1998, Iron release from human monocytes after erythrophagocytosis in vitro: an investigation in normal subjects and hereditary haemochromatosis patients. Blood, 92: 2511-2519.
17. Olivieri, N., 1998, Thalassaemia: clinical management. Baillieres Clin. Haematol., 11: 147-162.
18. Olivieri, N.F., and Brittenham, G.M., 1997, Iron-chelating therapy and the treatment of thalassemia. Blood, 89: 739-761.
19. Ricketts, C., Jacobs, A., and Cavill, I., 1975, Ferrokinetics and erythropoiesis in man: the measurement of effective erythropoiesis, ineffective erythropoiesis and red cell lifespan using 59Fe. Br. J. Haematol., 31: 65-75.
20. Roest, M., van der Schouw, Y.T., de Valk, B., Marx, J.J.M., Tempelman, M.J., de Groot, P.G., Sixma, J.J., and Banga, J.D., 1999, Heterozygosity for a hereditary haemochromatosis gene is associated with cardiovascular death in women. Circulation, 100: 1268-1273.
21. Santos, M., de Sousa, M., and Marx, J.J.M., 2000, Regulation of intracellular iron levels in iron-acceptor and iron-donor cells. Transfus. Sci., 23: 225-235.
22. van Asbeck, B.S., Georgiou, N.A., van der Bruggen, T., Oudshoorn, M., Nottet, H.S., and Marx, J.J.M., 2001, Anti-HIV effect of iron chelators: different mechanisms involved. J. Clin. Virol., 20: 141-147.
23. Voest, E.E., Neijt, J.P., Keunen, J.E., Dekker, A.W., van Asbeck, B.S., Nortier, J.W., Ros, F.E., and Marx, J.J.M., 1993, Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemother. Pharmacol., 31: 357-362.
24. Voest, E.E., Vreugdenhil, G., and Marx, J.J.M., 1994, Iron-chelating agents in non-iron overload conditions. Ann. Intern. Med., 120, 490-499.